Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1969 1
1975 1
1976 1
1977 2
1983 2
1985 2
1986 2
1987 3
1988 5
1989 2
1990 7
1991 7
1992 10
1993 1
1994 5
1995 7
1996 4
1997 3
1998 1
1999 11
2000 10
2001 12
2002 8
2003 11
2004 9
2005 10
2006 16
2007 12
2008 13
2009 15
2010 16
2011 11
2012 9
2013 17
2014 21
2015 35
2016 49
2017 38
2018 53
2019 42
2020 38
2021 37
2022 38
2023 36
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

579 results

Results by year

Filters applied: . Clear all
Page 1
Legg-Calvé-Perthes disease.
Leroux J, Abu Amara S, Lechevallier J. Leroux J, et al. Orthop Traumatol Surg Res. 2018 Feb;104(1S):S107-S112. doi: 10.1016/j.otsr.2017.04.012. Epub 2017 Nov 16. Orthop Traumatol Surg Res. 2018. PMID: 29155310 Free article. Review.
Surgery is now performed considerably less often than in the past, as it is effective only in patients with lateral pillar group B or B/C disease with onset after eight years of age. In other situations, therapeutic abstention is recommended....
Surgery is now performed considerably less often than in the past, as it is effective only in patients with lateral pillar group B or …
Structure, heterogeneity and developability assessment of therapeutic antibodies.
Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, Nowak C, Xiang T, Dong DD, Sun J, Beck A, Liu H. Xu Y, et al. MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17. MAbs. 2019. PMID: 30543482 Free PMC article. Review.
Rational HIV immunogen design to target specific germline B cell receptors.
Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. Jardine J, et al. Science. 2013 May 10;340(6133):711-6. doi: 10.1126/science.1234150. Epub 2013 Mar 28. Science. 2013. PMID: 23539181 Free PMC article.
When multimerized on nanoparticles, this immunogen (eOD-GT6) activates germline and mature VRC01-class B cells. Thus, eOD-GT6 nanoparticles have promise as a vaccine prime. ...
When multimerized on nanoparticles, this immunogen (eOD-GT6) activates germline and mature VRC01-class B cells. Thus, eOD-GT6 nanopar …
B cell targeting by molecular adjuvants for enhanced immunogenicity.
Sicard T, Kassardjian A, Julien JP. Sicard T, et al. Expert Rev Vaccines. 2020 Nov;19(11):1023-1039. doi: 10.1080/14760584.2020.1857736. Epub 2020 Dec 24. Expert Rev Vaccines. 2020. PMID: 33252273 Review.
Molecular adjuvants are a specific subclass of adjuvants where ligands of known immune-modulatory receptors are directly fused to an antigen. Co-stimulation of the B cell receptor (BCR) and immune-modulatory receptors through this strategy can augment downstream signaling …
Molecular adjuvants are a specific subclass of adjuvants where ligands of known immune-modulatory receptors are directly fused to an antigen …
Erdheim-Chester disease.
Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, Amoura Z. Haroche J, et al. Rheum Dis Clin North Am. 2013 May;39(2):299-311. doi: 10.1016/j.rdc.2013.02.011. Epub 2013 Mar 14. Rheum Dis Clin North Am. 2013. PMID: 23597965 Review.
Erdheim-Chester disease.
Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, Amoura Z. Haroche J, et al. Curr Rheumatol Rep. 2014 Apr;16(4):412. doi: 10.1007/s11926-014-0412-0. Curr Rheumatol Rep. 2014. PMID: 24532298 Review.
Clinical, phenotypic and genetic landscape of case reports with genetically proven inherited disorders of vitamin B(12) metabolism: A meta-analysis.
Wiedemann A, Oussalah A, Lamireau N, Théron M, Julien M, Mergnac JP, Augay B, Deniaud P, Alix T, Frayssinoux M, Feillet F, Guéant JL. Wiedemann A, et al. Cell Rep Med. 2022 Jul 19;3(7):100670. doi: 10.1016/j.xcrm.2022.100670. Epub 2022 Jun 27. Cell Rep Med. 2022. PMID: 35764087 Free PMC article.
Inherited disorders of B(12) metabolism produce a broad spectrum of manifestations, with limited knowledge of the influence of age and the function of related genes. We report a meta-analysis on 824 patients with a genetically proven diagnosis of an inherited disorder of v …
Inherited disorders of B(12) metabolism produce a broad spectrum of manifestations, with limited knowledge of the influence of age an …
Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis.
Broséus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, Schneider C, Dartigeas C, Roos-Weil D, Quinquenel A, Moulin C, Ott G, Blanchet O, Tomowiak C, Lazarian G, Rouyer P, Chteinberg E, Bernhart SH, Tournilhac O, Gauchotte G, Lomazzi S, Chapiro E, Nguyen-Khac F, Chery C, Davi F, Hunault M, Houlgatte R, Rosenwald A, Delmer A, Meyre D, Béné MC, Thieblemont C, Lichter P, Ammerpohl O, Guéant JL; ICGC MMML-Seq Consortium; Guièze R, Martin-Subero JI, Cymbalista F, Feugier P, Siebert R, Stilgenbauer S. Broséus J, et al. Nat Commun. 2023 Jan 19;14(1):309. doi: 10.1038/s41467-022-34642-6. Nat Commun. 2023. PMID: 36658118 Free PMC article.
Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). We characterize 58 primary human RS samples by genome-wide DNA methylation and whole-transcriptome profiling. .. …
Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into aggressive lymphoma, most commonly diffuse large B …
Optimizing hepatitis B vaccination in prison.
Perrodeau F, Pillot-Debelleix M, Vergniol J, Lemonnier F, Receveur MC, Trimoulet P, Raymond I, Le Port G, Gromb-Monnoyeur S. Perrodeau F, et al. Med Mal Infect. 2016 Mar;46(2):96-9. doi: 10.1016/j.medmal.2016.01.002. Epub 2016 Feb 19. Med Mal Infect. 2016. PMID: 26905392
OBJECTIVE: We aimed to establish the current status of hepatitis B virus (HBV) vaccination in prison. METHODS: We carried out two evaluations within a 1-year interval with inmates incarcerated for 6 to 12 months. ...
OBJECTIVE: We aimed to establish the current status of hepatitis B virus (HBV) vaccination in prison. METHODS: We carried out two eva …
579 results